Nasdaq leads stocks higher 📈

Large-caps gained on Wednesday, while the Russ2K lost ground.                                                                                                                                                                                                                                                                                                                                                                                                                 June 26, 2024 | [Read Online]( Good Afternoon! Hey, everyone. It's Adam from Elite Trade Club. Here’s what moved the market today. Markets 📈 Large-cap stocks edged higher on Wednesday, led by the Nasdaq for the second day in a row. The small-cap Russ2K lost half a point. - DJIA [<0.1%] - S&P 500 [+0.1%] - Nasdaq [+0.5%] - Russell 2K [-0.3%] [This Tiny Stock Could Be a Game-Changer]( Antibiotic-resistant superbugs are emerging as some of the deadliest threats in modern healthcare. Yet, a little-known company's breakthrough nanotechnology might hold the key to combating them. This groundbreaking innovation has the potential to address a $40.8 billion crisis in hospitals and significantly enhance patient safety. [Get the Details on this Groundbreaking Stock Here »]( » Want an Ad-Free Experience + Top Growth Stock Picks? [Upgrade Now!]( Market-Moving News 📈 Southwest Airlines Lowers Revenue Forecast Due to Changing Booking Patterns 📉 Southwest Airlines cut its second-quarter revenue forecast on Wednesday, attributing the revision to shifting booking patterns. The airline now expects revenue per available seat mile (RASM) to decrease by 4% to 4.5% year-over-year, a steeper decline than the previously estimated 1.5% to 3.5%. Rising Costs 📊 Southwest also adjusted its expectations for unit expenses, excluding fuel, which are now projected to rise by up to 7.5% over the previous year, as opposed to no change initially expected. Additionally, the airline's capacity is forecasted to grow by as much as 9%, compared to the flat growth previously anticipated. Despite these challenges, Southwest still expects record quarterly operating revenue in the second quarter. Competition ✈️ The airline industry is experiencing record passenger numbers, but increased costs and capacity growth are putting pressure on fares and profits. Southwest cited the need to adapt its revenue management strategies to current booking patterns as the primary reason for the reduced RASM expectations. In contrast, competitors like Delta and United have benefited from a surge in international travel and higher demand for premium seating. Activist Pressure 💼 Southwest is facing pressure from activist investor Elliott Management, which renewed its call for CEO Bob Jordan and Chairman Gary Kelly to be replaced. Elliott criticized the leadership for failing to adapt to the modern airline industry, citing the revised revenue outlook as evidence of the need for fundamental leadership changes. Potential Initiatives 💡 In response to these challenges, Southwest has expressed confidence in its leadership and is considering new revenue initiatives such as seating assignments and premium seating options. These changes would represent significant shifts from the company’s traditional business model, which has remained profitable for most of the past five decades. "We will adapt as our customers’ needs adapt," CEO Bob Jordan said at a recent industry event. Top Winners and Losers 🔥 CareMax [CMAX] $3.41 (+79.4%) rebounded from a sell-off that began after it announced changes to a crucial credit agreement earlier this week. Syntec Optics [OPTX] $3.85 (+63.8%) exploded suddenly despite no obvious news, but it lost most of its gains by the time the session closed. TRxADE Health [MEDS] $11.85 (+35.1%) published its Form 10-Q quarterly report early this morning, prompting a sudden rally. Bluejay Diagnostics [BJDX] $1.63 (40.7%) said a SYMON-1 study of Symphony IL-6 suggeste a prediction of mortality in sepsis patients. Gri Bio [GRI] $1.83 (38.3%) registered for a public offering of 2.238 million shares of common stock, plus accompanying warrants. Lyell Immunopharma [LYEL] $1.30 (36.0%) reported a patient death during a Phase 1 trial of its CAR-T Cell therapy LYL797. That's it for today! Please, write us back, and let us know what you think of the Closing Bell Roundup. We're always eager to hear feedback from our members! Thanks for reading. I'll see you at the next open! Best Regards, — Adam G. Elite Trade Club Text ELITESTOCKS to 47121 or [click here]( to get our alerts on your mobile device, and never miss another fast-moving stock! P.S. Just like this newsletter, it's 100% free*, and you can stop at any time by replying STOP. [Sign Up for Mobile Alerts Now]( [Privacy Policy]( | [Advertiser Disclosure]( [tw]( [ig]( [yt]( [tk]( *Standard message/carrier rates may apply. Legal Stuff: Stocks featured in this newsletter are for entertainment purposes only. You should not base any investment decisions on information contained in my newsletter. Stocks featured in this newsletter may be owned by owners/operators of this website, which could impact our ability to remain unbiased. Please consult a financial advisor before making any trading decisions. I may earn a small commission from links placed inside these emails. [Privacy Policy]( | [Terms of Service]( Update your email preferences or unsubscribe [here]( © 2024 Elite Trade Media LLC 1969 Alafaya Tr., Suite #247 Orlando, Florida 32828, United States of America [[beehiiv logo]Powered by beehiiv]( [Terms of Service](